ESMO in Focus Webinar - Lung Cancer 2025

Description

This ESMO in Focus Webinar presented selected highlights of the ESMO Congress 2024 and ESMO Asia 2024.

This webinar focused on the practice-changing studies and new science presented on lung cancer, and aimed to address how these new developments should be integrated into clinical practice.

The programme provided an expert overview and discussion of the latest developments in the management of patients with lung cancer. Important abstracts, including late breaking, were put into perspective in relation to clinical practice. Finally, the experts addressed issues of particular interest to participants in a Q&A session.

References

630MO - First-line (1L) osimertinib (osi) ± platinum-pemetrexed chemotherapy (CTx) for EGFR-mutated (EGFRm) advanced non-small cell lung cancer (NSCLC): FLAURA2 Asian cohort

LBA55 - Mechanisms of acquired resistance to first-line amivantamab plus lazertinib versus osimertinib in patients with EGFR-mutant advanced non-small cell lung cancer: An early analysis from the phase III MARIPOSA study

1241MO - Osimertinib (osi) after definitive chemoradiotherapy (CRT) in unresectable (UR) stg III EGFRm NSCLC: Analyses of CNS and distant progression from the phase III LAURA study

LBA6 - PACIFIC-5: A phase III study of consolidation durvalumab (D) in patients (pts) with unresectable stage III NSCLC and no progression after concurrent or sequential chemoradiotherapy (cCRT or sCRT)

1206MO - ALINA: Exploratory biomarker analyses in patients (pts) with resected ALK+ non-small cell lung cancer (NSCLC) treated with adjuvant alectinib vs chemotherapy (chemo)

LBA50 - Perioperative nivolumab (NIVO) v placebo (PBO) in patients (pts) with resectable NSCLC: Clinical update from the phase III CheckMate 77T study

LBA81 - Durvalumab (D) as consolidation therapy in limited-stage SCLC (LS-SCLC): Outcomes by prior concurrent chemoradiotherapy (cCRT) regimen and prophylactic cranial irradiation (PCI) use in the ADRIATIC trial